Oxurion NV (BR:OXUR) — Market Cap & Net Worth
Market Cap & Net Worth: Oxurion NV (OXUR)
Oxurion NV (BR:OXUR) has a market capitalization of $311.42K (€266.37K) as of May 2, 2026. Listed on the BR stock exchange, this Belgium-based company holds position #30701 globally and #113 in its home market, demonstrating a -9.52% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Oxurion NV's stock price €0.00 by its total outstanding shares 70098394 (70.10 Million). Analyse how efficiently does Oxurion NV generate cash to see how efficiently the company converts income to cash.
Oxurion NV Market Cap History: 2015 to 2026
Oxurion NV's market capitalization history from 2015 to 2026. Data shows change from $2.95 Trillion to $311.42K (-78.21% CAGR).
Index Memberships
Oxurion NV is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
BEL All Share
BSPT
|
$806.02 Billion | 0.00% | #107 of 108 |
Weight: Oxurion NV's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Oxurion NV Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Oxurion NV's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
6556.19x
Oxurion NV's market cap is 6556.19 times its annual revenue
Latest Price to Earnings (P/E) Ratio
165.28x
Oxurion NV's market cap is 165.28 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $2.95 Trillion | $11.20 Million | -$37.88 Million | 263465.44x | N/A |
| 2016 | $2.07 Trillion | $7.10 Million | -$60.31 Million | 291747.74x | N/A |
| 2017 | $2.77 Trillion | $5.81 Million | $22.79 Million | 477185.77x | 121662.69x |
| 2018 | $2.97 Trillion | $5.32 Million | -$38.47 Million | 557645.96x | N/A |
| 2019 | $2.42 Trillion | $3.95 Million | -$51.83 Million | 612669.91x | N/A |
| 2020 | $2.09 Trillion | $2.08 Million | -$28.01 Million | 1007643.67x | N/A |
| 2021 | $1.49 Trillion | $1.13 Million | -$29.16 Million | 1319375.34x | N/A |
| 2022 | $15.57 Billion | $595.00K | -$31.68 Million | 26169.67x | N/A |
| 2023 | $737.57 Million | $263.00K | -$18.97 Million | 2804.45x | N/A |
| 2024 | $19.67 Million | $3.00K | $119.00K | 6556.19x | 165.28x |
Competitor Companies of OXUR by Market Capitalization
Companies near Oxurion NV in the global market cap rankings as of May 2, 2026.
Key companies related to Oxurion NV by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Oxurion NV Historical Marketcap From 2015 to 2026
Between 2015 and today, Oxurion NV's market cap moved from $2.95 Trillion to $ 311.42K, with a yearly change of -78.21%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €311.42K | -47.22% |
| 2025 | €590.06K | -97.00% |
| 2024 | €19.67 Million | -97.33% |
| 2023 | €737.57 Million | -95.26% |
| 2022 | €15.57 Billion | -98.95% |
| 2021 | €1.49 Trillion | -28.92% |
| 2020 | €2.09 Trillion | -13.39% |
| 2019 | €2.42 Trillion | -18.51% |
| 2018 | €2.97 Trillion | +7.01% |
| 2017 | €2.77 Trillion | +33.77% |
| 2016 | €2.07 Trillion | -29.75% |
| 2015 | €2.95 Trillion | -- |
End of Day Market Cap According to Different Sources
On May 2nd, 2026 the market cap of Oxurion NV was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $311.42K USD |
| MoneyControl | $311.42K USD |
| MarketWatch | $311.42K USD |
| marketcap.company | $311.42K USD |
| Reuters | $311.42K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Oxurion NV
Oxurion NV, a biopharmaceutical company, develops medicines to prevent blindness in Belgium. The company is developing ophthalmic treatments to preserve vision for patients with retinal disorders, including geographic atrophy and age-related macular degeneration. The company was formerly known as ThromboGenics NV and changed its name to Oxurion NV in September 2018. Oxurion NV was founded in 1991… Read more